Table 1.

Approved indications and currently approved and reimbursed treatments for secukinumab in Italy, along with their posology

Secukinumab indication	Currently approved and reimbursed treatments in Italy (maintenance year)
PsO: moderate-to-severe plaque Pso in adult patients who are candidates for systemic therapy or phototherapy	Secukinumab 300 mg monthly, adalimumab 40 mg every 2 weeks, etanercept 50 mg once weekly, ustekinumab 45 mg every 12 weeks, ustekinumab 90 mg every 12 weeks, infliximab 5 mg/kg, every 8 weeks
PsA: active PsA in adult patients when the response to previous DMARD therapy has been inadequate	Secukinumab 300 mg monthly for patients with concomitant moderate-to-severe plaque Pso or who are anti-TNFα IR, secukinumab 150 mg monthly for all other patients, adalimumab 40 mg every 2 weeks, certolizumab 200 mg every 2 weeks, etanercept 50 mg once weekly, golimumab 50 mg monthly, ustekinumab 45 mg every 12 weeks, infliximab 5 mg/kg every 8 weeks, apremilasta 30 mg twice daily
AS: active AS in adults who have responded inadequately to conventional therapy	Secukinumab 150 mg monthly, adalimumab 40 mg every 2 weeks, certolizumab 200 mg every 2 weeks, etanercept 50 mg once weekly, golimumab 50 mg monthly, infliximab 5 mg/kg every 8 weeks

Notes: Posology was obtained from products SmPC; please refer to last approved SmPC for loading doses where applied. Last reimbursement status for each drug can be found on the Italian Official Journal website.⁷²

^aNot reimbursed in Pso, reimbursed in PsA for patients which are intolerant or inadequate to biologic therapies.

Abbreviations: AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; IR, inadequate responders; PsA, psoriatic arthritis; Pso, psoriasis; SmPC, summary of product characteristics; TNF, tumor necrosis factor.